Top

Published in:

01-11-2014 | Research Article

Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer

Authors: Qinchuan Wang, Jichun Zhou, Jufeng Guo, Rongyue Teng, Jianguo Shen, Yasheng Huang, Shuduo Xie, Qun Wei, Wenhe Zhao, Wenjun Chen, Xiaoming Yuan, Yongxia Chen, Linbo Wang

Published in: Tumor Biology | Issue 11/2014

Abstract

The main purpose of this study is to investigate the interactions between Lin28 and Her2 in gastric cancer. Lin28 and Her2 expression were evaluated in surgically resected samples of 298 gastric cancer patients using immunohistochemical staining. The correlations between Lin28/Her2 expression and clinical variables were retrospectively analyzed. The mRNA level of LIN28 and HER2 was detected by reverse-transcriptase polymerase chain reaction. Among all gastric cancer patients, 33.9 % (101/298) were determined as Her2-positive, and 43.0 % (128/298) were defined as Lin28-positive. Lin28 was significantly associated with Her2, advanced tumor stage, lesion size, and Ki67 level (p < 0.05 for each). Kaplan-Meier analysis illustrated that both Lin28 and Her2 are poor prognostic factors in gastric cancer; Lin28(+)/Her2(+) patients have the poorest survival (median survival = 17 months, p < 0.01). Multivariate Cox analysis showed that Lin28 is a significant prognostic factor (hazard ratio (HR) = 1.79, 95 % confidence interval (CI) 1.23–2.62). Further stratification analysis indicated that Lin28 may be a prognostic factor in chemotherapy. In vitro data on MKN-28 and MKN-45 cells showed that Lin28 can upregulate Her2 expression at translational level. Both Lin28 and Her2 are poor prognostic factors in gastric cancer. Lin28 may regulate Her2 post-transcriptionally in gastric cancer cells, which indicates it might be a potential target in the treatment of gastric cancer.

Available only for authorised users

Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef

Wong H, Yau T. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist. 2012;17(3):346–58.PubMedCentralPubMedCrossRef

de Gonzalez de Castro D et al. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther. 2013;93(3):252–9.PubMedCentralPubMedCrossRef

Albain KS et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.PubMedCentralPubMedCrossRef

Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34.PubMedCrossRef

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.PubMedCrossRef

Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med. 2005;353(16):1734–6.PubMedCrossRef

Ajani JA et al. Gastric cancer. J Natl Compr Canc Netw. 2010;8(4):378–409.PubMed

Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.PubMedCrossRef

10.

Gordon MA et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24(7):1754–61.PubMedCentralPubMedCrossRef

11.

Martinez NJ, Gregory RI. MicroRNA gene regulatory pathways in the establishment and maintenance of ESC identity. Cell Stem Cell. 2010;7(1):31–5.PubMedCrossRef

12.

Matera AG, Terns RM, Terns MP. Non-coding RNAs: lessons from the small nuclear and small nucleolar RNAs. Nat Rev Mol Cell Biol. 2007;8(3):209–20.PubMedCrossRef

13.

Zhu H et al. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011;147(1):81–94.PubMedCentralPubMedCrossRef

14.

Lv K et al. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. PLoS One. 2012;7(7):e40008.PubMedCentralPubMedCrossRef

15.

Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene. 2010;29(14):2153–9.PubMedCrossRef

16.

Oh JS et al. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys. 2010;76(1):5–8.PubMedCrossRef

17.

Saiki Y et al. Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells. Ann Surg Oncol. 2009;16(9):2638–44.PubMedCrossRef

18.

Xu C et al. Positive expression of Lin28 is correlated with poor survival in gastric carcinoma. Med Oncol. 2013;30(1):382.PubMedCrossRef

19.

Piskounova E et al. Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem. 2008;283(31):21310–4.PubMedCrossRef

20.

Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science. 2008;320(5872):97–100.PubMedCentralPubMedCrossRef

21.

Piskounova E et al. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell. 2011;147(5):1066–79.PubMedCentralPubMedCrossRef

22.

Feng C et al. Lin28 regulates HER2 and promotes malignancy through multiple mechanisms. Cell Cycle. 2012;11(13):2486–94.PubMedCrossRef

23.

Malik F et al. Lin28 and HER2: two stem cell regulators conspire to drive aggressive breast cancer. Cell Cycle. 2012;11(15):2780–1.PubMedCentralPubMedCrossRef

24.

Teng RY et al. The relationship between Lin28 and the chemotherapy response of gastric cancer. Oncol Targets Ther. 2013;6:1341–5.CrossRef

25.

Xu CY et al. Prognostic role of estrogen receptor alpha and estrogen receptor beta in gastric cancer. Ann Surg Oncol. 2010;17(9):2503–9.PubMedCrossRef

26.

Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2) 101–12.

27.

Kim KC et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 2011;18(10):2833–40.PubMedCrossRef

28.

Janjigian YY et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23(10):2656–62.PubMedCrossRef

29.

Sakurai M et al. LIN28: a regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. J Steroid Biochem Mol Biol. 2012;131(3–5):101–6.PubMedCrossRef

30.

Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135(1):55–62.PubMedCentralPubMed

31.

Thornton JE, Gregory RI. How does Lin28 let-7 control development and disease? Trends Cell Biol. 2012;22(9):474–82.PubMedCentralPubMedCrossRef

32.

Huang Y. A mirror of two faces: Lin28 as a master regulator of both miRNA and mRNA. Wiley Interdiscip Rev RNA. 2012;3(4):483–94.PubMedCrossRef

33.

Fang C, Zhao Y, Guo B. MiR-199b-5p targets HER2 in breast cancer cells. J Cell Biochem. 2013;114(7):1457–63.PubMedCrossRef

34.

Fassan M et al. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. Hum Pathol. 2013;44(9):1804–10.PubMedCrossRef

Title: Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer
Authors: Qinchuan Wang
Jichun Zhou
Jufeng Guo
Rongyue Teng
Jianguo Shen
Yasheng Huang
Shuduo Xie
Qun Wei
Wenhe Zhao
Wenjun Chen
Xiaoming Yuan
Yongxia Chen
Linbo Wang
Publication date: 01-11-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 11/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2481-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2014

Polymorphism in interleukin 21 gene is associated with decreased susceptibility to diffuse large B cell lymphoma

Upregulation of miR-513b inhibits cell proliferation, migration, and promotes apoptosis by targeting high mobility group-box 3 protein in gastric cancer

RETRACTED ARTICLE: Inhibition of epidermal growth factor receptor signaling prohibits metastasis of gastric cancer via downregulation of MMP7 and MMP13

Bufalin induces cell cycle arrest and apoptosis in gallbladder carcinoma cells

TGF-β1 mediates estrogen receptor-induced epithelial-to-mesenchymal transition in some tumor lines

TES was epigenetically silenced and suppressed the epithelial–mesenchymal transition in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer